Diseases in which fibrosis plays a major role account for an estimated 45% of deaths in the western world

Fibrosis can affect virtually all organs and tissues. In the case of physical or vascular trauma, repairative fibrosis such as wound healing is critical for survival. However, when the fibrotic response becomes dysregulated either as an extended response to injury (e.g. cardiac fibrosis) or as a secondary response to proinflammaory cytokines/growth factors (e.g. cancer stroma) it will result in diseases with devastating pathologies.

NovoMedix has developed a platform technology that enables the development of orally available small molecules with wide therapeutic windows to treat fibrotic diseases. The initial targeted indications will be Heart Failure and Triple Negative Breast Cancer (TNBC) with the goal of rapid delivery of this first-in-class therapy to patients.


November 2nd, 2016 - NovoMedix is 1 of 5 NCI sponsored companies to present at the Life Sciences Summit in New York City.

June 8th, 2016 - NovoMedix is sponsored by the NCI to participate in the Innovation Zone at BIO International (San Francisco, CA) and selected to present at the Startup Stadium.

April 1st, 2016 - NovoMedix is the recipient of NIH SBIR Phase I Grant (1 R43 HL131356-01A1) Title: Novel antifibrotic small molecules for the treatment of heart failure.

Get in touch